# Sionna Therapeutics, Inc.: overview SION · Nasdaq · CIK 2036042 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/sion.md) · [Financials](/companies/sion/financials.md) · [Filings](/companies/sion/filings.md) · [Insiders](/companies/sion/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | period not labelled (2024-09-30) | period not labelled (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(5.67)](/filings/0001628280-25-049251.md) | not reported | [(0.62)](/filings/0001628280-26-033876.md) | [(0.41)](/filings/0001628280-26-053839.md) | [(0.46)](/filings/0001628280-25-049251.md) | not reported | [(0.60)](/filings/0001628280-26-033876.md) | [(0.66)](/filings/0001628280-26-053839.md) | | Free cash flow | $m | [(17.7) d](/filings/0001628280-25-049251.md) | [(11.8) d](/filings/0001628280-26-012996.md) | [(16.4)](/filings/0001628280-26-033876.md) | [(18.2) d](/filings/0001628280-26-053839.md) | [(15.3) d](/filings/0001628280-25-049251.md) | [(16.8) d](/filings/0001628280-26-012996.md) | [(21.8)](/filings/0001628280-26-033876.md) | [(22.2) d](/filings/0001628280-26-053839.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | | Revenue | $m | not reported | not reported | | Gross margin | % | not reported | not reported | | Operating margin | % | not reported | not reported | | Net margin | % | not reported | not reported | | Diluted EPS | $ per share | [(15.99)](/filings/0001628280-26-012996.md) | [(1.88)](/filings/0001628280-26-012996.md) | | Free cash flow | $m | [(52.8)](/filings/0001628280-26-012996.md) | [(66.7)](/filings/0001628280-26-012996.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sion/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $435.7m | 9,905,045 | | Unchanged | | [TPG GP A, LLC](/funds/1903793.md) | 2026-06-30 | $285.7m | 6,494,962 | | Unchanged | | [VIKING GLOBAL INVESTORS LP](/funds/1103804.md) | 2026-06-30 | $140.6m | 3,195,181 | | Unchanged | | [Atlas Venture Life Science Advisors, LLC](/funds/1917529.md) | 2026-06-30 | $131.8m | 2,995,602 | | Unchanged | | [ORBIMED ADVISORS LLC](/funds/1055951.md) | 2026-06-30 | $112.4m | 2,555,877 | | Reduced −974,825 | | [ENAVATE SCIENCES GP, LLC](/funds/1953107.md) | 2026-06-30 | $109.0m | 2,478,030 | | Unchanged | | [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $70.4m | 1,600,000 | | Added +1,450,000 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $64.9m | 1,474,769 | | Added +178,902 | | [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $64.1m | 1,490,508 | | Added +25,494 | | [JENNISON ASSOCIATES LLC](/funds/53417.md) | 2026-06-30 | $51.6m | 1,172,133 | | Reduced −279,087 | ## Recent filings [All 229 filings](/companies/sion/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-21 | 18:57 ET | [SCHEDULE 13D/A](/filings/0001346824-26-000239.md) | Ownership report, active investor, amended | 0001346824-26-000239 | | 2026-09-14 | 16:10 ET | [8-K](/filings/0001193125-26-390577.md) | 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-390577 | | 2026-08-10 | 07:15 ET | [8-K](/filings/0001193125-26-341230.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-341230 | | 2026-08-06 | 07:19 ET | [10-Q](/filings/0001628280-26-053839.md) | Quarterly report, period 2026-06-30 | 0001628280-26-053839 | | 2026-08-06 | 07:12 ET | [8-K](/filings/0001628280-26-053832.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-053832 | | 2026-06-18 | 16:05 ET | [8-K](/filings/0001628280-26-044263.md) | 5.07 Shareholder vote results | 0001628280-26-044263 | | 2026-05-12 | 07:17 ET | [10-Q](/filings/0001628280-26-033876.md) | Quarterly report, period 2026-03-31 | 0001628280-26-033876 | | 2026-05-12 | 07:08 ET | [8-K](/filings/0001628280-26-033870.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-033870 | | 2026-04-27 | 16:04 ET | [DEF 14A](/filings/0001628280-26-027489.md) | Proxy statement, period 2026-06-17 | 0001628280-26-027489 | | 2026-04-20 | 18:46 ET | [SCHEDULE 13D/A](/filings/0000947871-26-000456.md) | Ownership report, active investor, amended | 0000947871-26-000456 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-012996.md), filed Mar 2, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 2036042 - Tickers: SION - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.